One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

Data will be presented at an upcoming medical meeting and shared with health authorities as soon as possible, including the US Food and Drug Administration and the European Medicines Agency. If ...

Roche (ROG: SIX) has reported positive top-line results from the Phase III INShore study of Gazyva (obinutuzumab) in children ...

Roche’s phase III INShore study of Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome meets its primary endpoints: Basel Wednesday, October 29, 2025 ...

The randomized, open-label INSHORE trial (ClinicalTrials.gov Identifier: NCT05627557) evaluated the safety and efficacy of obinutuzumab in children and young adults in clinical remission aged 2 to 25 ...

Roche Holding (SWX:ROG) is grabbing attention after reporting statistically significant and clinically meaningful results ...

Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and yo ...